This was the stock's third consecutive day of losses.

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies targeting serious diseases. Under the agreement, City Therapeutics will use its ...

Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore.

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Biogen stock was muted Thursday after the biotech company beat Wall Street's first-quarter expectations, including strong sales for newcomer drugs Leqembi and Skyclarys. Leqembi, which partner ...

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $121.00. The company’s shares closed y ...

Shares of Biogen Inc. BIIB shed 1.79% to $133.06 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the Dow Jones Industrial Average DJIA remaining mostly ...